Bezlotoxumab (Zinplava®) is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.
|NCPE Assessment Process||Complete|
|Rapid review received||11/05/2017|
|Rapid review completed||14/06/2017|
|Rapid Review outcome||Full pharmacoeconomic evaluation recommended|
|Full pharmacoeconomic assessment commissioned by HSE||14/06/2017|
|Current Status||Company to not plan to submit|
The company do not plan to submit a HTA dossier to the NCPE therefore the cost effectiveness of the technology cannot be proven.